GLP1R and stomach disorder: As of now, there is limited clinical evidence surrounding the association of the use of novel second-line anti-diabetic drugs (SGLT2I, DPP4I and glucagon-like peptide-1 receptor agonist (GLP1a) on different types of gastric diseases.